Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Operations (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Cash from Operations for 7 consecutive years, with 27292000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 40.68% year-over-year to 27292000.0, compared with a TTM value of 107505000.0 through Dec 2025, up 166.83%, and an annual FY2025 reading of 107505000.0, up 166.83% over the prior year.
  • Cash from Operations was 27292000.0 for Q4 2025 at Keros Therapeutics, down from 3249000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 161171000.0 in Q1 2025 and bottomed at 46008000.0 in Q4 2024.
  • Average Cash from Operations over 5 years is 15504100.0, with a median of 25030500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations crashed 2299.09% in 2023, then surged 461.69% in 2025.
  • Year by year, Cash from Operations stood at 19565000.0 in 2021, then decreased by 9.6% to 21443000.0 in 2022, then decreased by 18.73% to 25459000.0 in 2023, then crashed by 80.71% to 46008000.0 in 2024, then skyrocketed by 40.68% to 27292000.0 in 2025.
  • Business Quant data shows Cash from Operations for KROS at 27292000.0 in Q4 2025, 3249000.0 in Q3 2025, and 29623000.0 in Q2 2025.